{
    "clinical_study": {
        "@rank": "45406", 
        "arm_group": {
            "arm_group_label": "Recormon (epoetin beta)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study examines the safety profile and effectiveness of Recormon treatment in adult\n      patients with symptomatic anemia associated with low/intermediate-1-risk MDS. The design\n      consists of a 2-week baseline phase, a 12-week treatment phase where Recormon dosage will be\n      adjusted on the basis of erythroid response and end-of-study visit."
        }, 
        "brief_title": "An Open-Label Study of Recormon (Epoetin Beta) Treatment in Anemic Patients With Myelodysplastic Syndromes", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients with low and intermediate-1 risk myelodysplastic syndromes (MDS)\n\n          -  No previous treatment with hematopoietic growth factors within 3 months prior to\n             study entry\n\n          -  Symptomatic anemia (Hb < 10 g/dl)\n\n          -  Serum erythropoietin < 500 mU/ml\n\n          -  Require no red blood cell transfusion or dependent on < 2 units/month\n\n          -  Clinically stable for at least one month prior to entry into the study\n\n        Exclusion Criteria:\n\n          -  Contraindications or hypersensitivity to Recormon treatment\n\n          -  Poorly controlled hypertension\n\n          -  History of acute myeloid leukemia (AML) or high risk for AML\n\n          -  Administration of another investigational drug within 1 month before screening or\n             planned during the study period\n\n          -  Women who are pregnant or breast feeding, or women of childbearing potential without\n             effective contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145026", 
            "org_study_id": "ML29005"
        }, 
        "intervention": {
            "arm_group_label": "Recormon (epoetin beta)", 
            "description": "Injectable solution of Recormon 30,000 - 60,000 IU per week given subcutaneously over the 12-week treatment phase.", 
            "intervention_name": "epoetin beta [Recormon]", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Epoetin Alfa"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 20, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Prospective Open-label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-risk Myelodysplastic Syndrome (MDS)", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML29005 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Thailand:Food and Drug Administration Ministry of Public Health"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events (AEs)", 
            "safety_issue": "No", 
            "time_frame": "Approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145026"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Erythroid response", 
            "safety_issue": "No", 
            "time_frame": "At week 12"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}